Tumour vascularization: sprouting angiogenesis and beyond
暂无分享,去创建一个
[1] S. Rafii,et al. Placental growth factor reconstitutes hematopoiesis by recruiting VEGFR1+ stem cells from bone-marrow microenvironment , 2002, Nature Medicine.
[2] N. Goldstein,et al. Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors. , 1997, The American journal of pathology.
[3] A. Karsan,et al. Minimal Contribution of Marrow-Derived Endothelial Precursors to Tumor Vasculature1 , 2005, The Journal of Immunology.
[4] W. Gerald,et al. Effect of angiogenesis inhibition by Id loss and the contribution of bone-marrow-derived endothelial cells in spontaneous murine tumors. , 2003, Cancer cell.
[5] R W Blamey,et al. Prognostic value of lymphovascular invasion in women with lymph node negative invasive breast carcinoma. , 2006, European journal of cancer.
[6] Thomas N. Sato,et al. Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. , 1997, Science.
[7] M. Rudek,et al. Reversible sideroblastic anemia associated with the tetracycline analogue COL‐3 , 2001, American journal of hematology.
[8] Oswald Wagner,et al. Lymphoma-specific genetic aberrations in microvascular endothelial cells in B-cell lymphomas. , 2004, The New England journal of medicine.
[9] M. Detmar,et al. The rediscovery of the lymphatic system: old and new insights into the development and biological function of the lymphatic vasculature. , 2002, Genes & development.
[10] M Buyse,et al. Non-small-cell lung carcinoma tumor growth without morphological evidence of neo-angiogenesis. , 1997, The American journal of pathology.
[11] J. Isner,et al. Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization. , 1999, Circulation research.
[12] L. Chin,et al. Epigenetic transdifferentiation of normal melanocytes by a metastatic melanoma microenvironment. , 2005, Cancer research.
[13] Tetsurou Matsumoto,et al. Current and future status of prostate cancer chemoprevention , 2006, Expert review of anticancer therapy.
[14] Arjun Deb,et al. Integrin Profile and In Vivo Homing of Human Smooth Muscle Progenitor Cells , 2004, Circulation.
[15] M. Hendrix,et al. Prostatic tumor cell plasticity involves cooperative interactions of distinct phenotypic subpopulations: Role in vasculogenic mimicry , 2002, The Prostate.
[16] E. Lee,et al. Circulating numbers of endothelial progenitor cells in patients with gastric and breast cancer. , 2003, Cancer letters.
[17] E. Rofstad,et al. Hypoxia promotes lymph node metastasis in human melanoma xenografts by up-regulating the urokinase-type plasminogen activator receptor. , 2002, Cancer research.
[18] Haruchika Masuda,et al. Ischemia- and cytokine-induced mobilization of bone marrow-derived endothelial progenitor cells for neovascularization , 1999, Nature Medicine.
[19] T. Iwanaga,et al. Hemodynamics in vasculogenic mimicry and angiogenesis of inflammatory breast cancer xenograft. , 2002, Cancer research.
[20] E. Manseau,et al. Vascular Permeability Factor/Vascular Endothelial Growth Factor Induces Lymphangiogenesis as well as Angiogenesis , 2002, The Journal of experimental medicine.
[21] P. Comoglio,et al. Sema4D induces angiogenesis through Met recruitment by Plexin B1. , 2005, Blood.
[22] P. Leder,et al. The IP-10 chemokine binds to a specific cell surface heparan sulfate site shared with platelet factor 4 and inhibits endothelial cell proliferation , 1995, The Journal of experimental medicine.
[23] D. Ribatti,et al. Microvascular density, vascular endothelial growth factor immunoreactivity in tumor cells, vessel diameter and intussusceptive microvascular growth in primary melanoma. , 2005, Oncology reports.
[24] K. Alitalo,et al. A Recombinant Mutant Vascular Endothelial Growth Factor-C that Has Lost Vascular Endothelial Growth Factor Receptor-2 Binding, Activation, and Vascular Permeability Activities* , 1998, The Journal of Biological Chemistry.
[25] S. Rafii,et al. Mobilization of Endothelial and Hematopoietic Stem and Progenitor Cells by Adenovector‐Mediated Elevation of Serum Levels of SDF‐1, VEGF, and Angiopoietin‐1 , 2001, Annals of the New York Academy of Sciences.
[26] M. Yoder,et al. Unresolved questions, changing definitions, and novel paradigms for defining endothelial progenitor cells. , 2005, Blood.
[27] E. Chavakis,et al. High-Mobility Group Box 1 Activates Integrin-Dependent Homing of Endothelial Progenitor Cells , 2007, Circulation research.
[28] K. Acharya,et al. Role of placenta growth factor in cardiovascular health. , 2002, Trends in cardiovascular medicine.
[29] A. Griffioen,et al. Bactericidal/permeability-increasing protein (BPI) inhibits angiogenesis via induction of apoptosis in vascular endothelial cells. , 2000, Blood.
[30] P. Pauwels,et al. Absence of lymphangiogenesis in ductal breast cancer at the primary tumor site. , 2007, Cancer letters.
[31] Shigeyoshi Itohara,et al. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis , 2000, Nature Cell Biology.
[32] Zhong Chen,et al. Does Vasculogenic Mimicry Exist in Astrocytoma? , 2005, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.
[33] Y. Lotan,et al. Lymphovascular invasion is independently associated with overall survival, cause-specific survival, and local and distant recurrence in patients with negative lymph nodes at radical cystectomy. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[34] G. Mann,et al. Targeting lymphangiogenesis to prevent tumour metastasis , 2006, British Journal of Cancer.
[35] P. Meltzer,et al. Vascular channel formation by human melanoma cells in vivo and in vitro: vasculogenic mimicry. , 1999, The American journal of pathology.
[36] M. Hendrix,et al. Molecular determinants of ovarian cancer plasticity. , 2001, The American journal of pathology.
[37] O. Fodstad,et al. Association of insulin-like growth factor binding protein-3 expression with melanoma progression , 2006, Molecular Cancer Therapeutics.
[38] Lars Holmgren,et al. Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases by a lewis lung carcinoma , 1994, Cell.
[39] Pamela F. Jones,et al. Isolation of Angiopoietin-1, a Ligand for the TIE2 Receptor, by Secretion-Trap Expression Cloning , 1996, Cell.
[40] T. Maione,et al. Inhibition of development of murine melanoma lung metastases by systemic administration of recombinant platelet factor 4. , 1995, Journal of the National Cancer Institute.
[41] D. Hanahan,et al. Lymphatic zip codes in premalignant lesions and tumors. , 2006, Cancer research.
[42] G. Yancopoulos,et al. Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. , 1999, Science.
[43] Paul S. Meltzer,et al. Expression and functional significance of VE-cadherin in aggressive human melanoma cells: Role in vasculogenic mimicry , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[44] C. Betsholtz,et al. Endothelial/Pericyte Interactions , 2005, Circulation research.
[45] Cun-Yu Wang,et al. Notch signaling in the regulation of tumor angiogenesis. , 2006, Trends in cell biology.
[46] D. Ruiter,et al. Presence of a fluid-conducting meshwork in xenografted cutaneous and primary human uveal melanoma. , 2002, Investigative ophthalmology & visual science.
[47] P. Meltzer,et al. Cooperative interactions of laminin 5 gamma2 chain, matrix metalloproteinase-2, and membrane type-1-matrix/metalloproteinase are required for mimicry of embryonic vasculogenesis by aggressive melanoma. , 2001, Cancer research.
[48] R. D'Amato,et al. Genetic heterogeneity of the vasculogenic phenotype parallels angiogenesis; Implications for cellular surrogate marker analysis of antiangiogenesis. , 2005, Cancer cell.
[49] Peter Carmeliet,et al. Angiogenesis in life, disease and medicine , 2005, Nature.
[50] M. Hendrix,et al. Targeting the Tumor Microenvironment with Chemically Modified Tetracyclines: Inhibition of Laminin 5 γ2 Chain Promigratory Fragments and Vasculogenic Mimicry1Supported by NIH/National Cancer Institute Grants CA83137 (to R. E. B. S.), CA80318, CA88043-02S1, and CA59702 (to M. J. C. H.).1 , 2002 .
[51] B. Döme,et al. Vascularization of cutaneous melanoma involves vessel co‐option and has clinical significance , 2002, The Journal of pathology.
[52] D. Yamashiro,et al. Vascular remodeling and clinical resistance to antiangiogenic cancer therapy. , 2004, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.
[53] H. Arakawa,et al. Netrin-1 and its receptors in tumorigenesis , 2004, Nature Reviews Cancer.
[54] K. Pantel,et al. In vitro differentiation of endothelial cells from AC133-positive progenitor cells. , 1999, Blood.
[55] N. Ferrara,et al. The biology of VEGF and its receptors , 2003, Nature Medicine.
[56] M. Hendrix,et al. Targeting the tumor microenvironment with chemically modified tetracyclines: inhibition of laminin 5 gamma2 chain promigratory fragments and vasculogenic mimicry. , 2002, Molecular cancer therapeutics.
[57] D. Curiel,et al. Genetically modified CD34+ cells exert a cytotoxic bystander effect on human endothelial and cancer cells. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.
[58] Michael Gnant,et al. Prognostic Value of Lymphangiogenesis and Lymphovascular Invasion in Invasive Breast Cancer , 2004, Annals of surgery.
[59] Dhara N. Amin,et al. Tumor-Associated Endothelial Cells with Cytogenetic Abnormalities , 2004, Cancer Research.
[60] D. Hanahan,et al. The Hallmarks of Cancer , 2000, Cell.
[61] B. Lane,et al. Reversible posterior leukoencephalopathy syndrome and bevacizumab. , 2006, The New England journal of medicine.
[62] A. Andres,et al. Vascular remodelling during the normal and malignant life cycle of the mammary gland , 2001, Microscopy research and technique.
[63] R. Kerbel. Tumor angiogenesis: past, present and the near future. , 2000, Carcinogenesis.
[64] M. Hendrix,et al. Effects of angiogenesis inhibitors on vascular network formation by human endothelial and melanoma cells. , 2004, Journal of the National Cancer Institute.
[65] D. Becker,et al. Antisense targeting of basic fibroblast growth factor and dibroblast growth factor receptor-1 in human melanomas blocks intratumoral angiogenesis and tumor growth , 1997, Nature Medicine.
[66] E C Nice,et al. Isolated lymphatic endothelial cells transduce growth, survival and migratory signals via the VEGF‐C/D receptor VEGFR‐3 , 2001, The EMBO journal.
[67] K. Alitalo,et al. VEGF guides angiogenic sprouting utilizing endothelial tip cell filopodia , 2003, The Journal of cell biology.
[68] R. Kalluri,et al. Distinct Antitumor Properties of a Type IV Collagen Domain Derived from Basement Membrane* , 2000, The Journal of Biological Chemistry.
[69] Thomas Hawighorst,et al. Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis , 2001, Nature Medicine.
[70] J. Isner,et al. Transplantation of ex vivo expanded endothelial progenitor cells for therapeutic neovascularization. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[71] J. Marx. A Boost for Tumor Starvation , 2003, Science.
[72] M. Karkkainen,et al. Lymphatic vasculature: development, molecular regulation and role in tumor metastasis and inflammation. , 2004, Trends in immunology.
[73] N. Itoh,et al. Evolution of the Fgf and Fgfr gene families. , 2004, Trends in genetics : TIG.
[74] S. Renninger,et al. Minor Contribution of Bone Marrow‐Derived Endothelial Progenitors to the Vascularization of Murine Gliomas , 2003, Brain pathology.
[75] Tatiana V. Petrova,et al. Lymphangiogenesis in development and human disease , 2005, Nature.
[76] G. Garcı́a-Cardeña,et al. Dose-dependent response of FGF-2 for lymphangiogenesis. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[77] B. Engelhardt,et al. Multistep Nature of Microvascular Recruitment of Ex Vivo–expanded Embryonic Endothelial Progenitor Cells during Tumor Angiogenesis , 2003, The Journal of experimental medicine.
[78] A. Mori,et al. Tumour plasticity and extravascular circulation in ECV304 human bladder carcinoma cells. , 2006, Anticancer research.
[79] M. Karkkainen,et al. Vascular endothelial growth factor C promotes tumor lymphangiogenesis and intralymphatic tumor growth. , 2001, Cancer research.
[80] P. Carmeliet,et al. Angiogenesis in cancer and other diseases , 2000, Nature.
[81] Michelle L. Varney,et al. IL-8 Directly Enhanced Endothelial Cell Survival, Proliferation, and Matrix Metalloproteinases Production and Regulated Angiogenesis1 , 2003, The Journal of Immunology.
[82] S. Hirakawa,et al. Hepatocyte growth factor promotes lymphatic vessel formation and function , 2005, The EMBO journal.
[83] Yihai Cao,et al. Update on therapeutic neovascularization. , 2005, Cardiovascular research.
[84] Eugene S. Kim,et al. Potent VEGF blockade causes regression of coopted vessels in a model of neuroblastoma , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[85] F. Liao,et al. Migration of monocytes across endothelium and passage through extracellular matrix involve separate molecular domains of PECAM-1 , 1995, The Journal of experimental medicine.
[86] Olivier Delattre,et al. Tumor cell plasticity in Ewing sarcoma, an alternative circulatory system stimulated by hypoxia. , 2005, Cancer research.
[87] N. Ferrara,et al. The 16K fragment of prolactin specifically inhibits basal or fibroblast growth factor stimulated growth of capillary endothelial cells. , 1991, Endocrinology.
[88] Steven A. Stacker,et al. VEGF-D promotes the metastatic spread of tumor cells via the lymphatics , 2001, Nature Medicine.
[89] M. Westphal,et al. Inhibition of glioma angiogenesis and growth in vivo by systemic treatment with a monoclonal antibody against vascular endothelial growth factor receptor-2. , 2001, Cancer research.
[90] A. Yayon,et al. Effects of modulation of basic fibroblast growth factor on tumor growth in vivo. , 1993, Journal of the National Cancer Institute.
[91] Yihai Cao,et al. Insulin-like growth factors 1 and 2 induce lymphangiogenesis in vivo , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[92] R. Folberg,et al. Demonstrating circulation in vasculogenic mimicry patterns of uveal melanoma by confocal indocyanine green angiography , 2008, Eye.
[93] P H Burri,et al. Scanning electron microscope study of the developing microvasculature in the postnatal rat lung , 1986, The Anatomical record.
[94] Napoleone Ferrara,et al. Angiogenesis as a therapeutic target , 2005, Nature.
[95] N. Yang,et al. Tumor-derived vascular endothelial growth factor up-regulates angiopoietin-2 in host endothelium and destabilizes host vasculature, supporting angiogenesis in ovarian cancer. , 2003, Cancer research.
[96] P. Corvol,et al. Angiogenesis and vascular architecture in pheochromocytomas: distinctive traits in malignant tumors. , 2002, The American journal of pathology.
[97] P. Dell’Era,et al. Fibroblast growth factor/fibroblast growth factor receptor system in angiogenesis. , 2005, Cytokine & growth factor reviews.
[98] K Anan,et al. Vascular endothelial growth factor and platelet-derived growth factor are potential angiogenic and metastatic factors in human breast cancer. , 1996, Surgery.
[99] P. Campochiaro,et al. Angiopoietin-2 is required for postnatal angiogenesis and lymphatic patterning, and only the latter role is rescued by Angiopoietin-1. , 2002, Developmental cell.
[100] B. Peters,et al. Contribution of bone marrow–derived endothelial cells to human tumor vasculature , 2005, Nature Medicine.
[101] A. Koch,et al. Angiogenesis as a target in rheumatoid arthritis , 2003, Annals of the rheumatic diseases.
[102] M. Turner,et al. Drug-induced lupus associated with COL-3: report of 3 cases. , 2001, Archives of Dermatology.
[103] P. Burri,et al. Optimality in the developing vascular system: Branching remodeling by means of intussusception as an efficient adaptation mechanism , 2002, Developmental dynamics : an official publication of the American Association of Anatomists.
[104] Takayuki Asahara,et al. Isolation of Putative Progenitor Endothelial Cells for Angiogenesis , 1997, Science.
[105] J. Berlin,et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. , 2004, The New England journal of medicine.
[106] M. Hendrix,et al. Focal adhesion kinase promotes the aggressive melanoma phenotype. , 2005, Cancer research.
[107] Till Acker,et al. Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions , 2001, Nature Medicine.
[108] S. Rafii,et al. Recruitment of Stem and Progenitor Cells from the Bone Marrow Niche Requires MMP-9 Mediated Release of Kit-Ligand , 2002, Cell.
[109] C. Heeschen,et al. Essential role of endothelial nitric oxide synthase for mobilization of stem and progenitor cells , 2003, Nature Medicine.
[110] J. Mei,et al. Tumor blood vessels formation in osteosarcoma: vasculogenesis mimicry. , 2004, Chinese medical journal.
[111] K. Alitalo,et al. Expression of the fms-like tyrosine kinase 4 gene becomes restricted to lymphatic endothelium during development. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[112] M. Skobe,et al. Molecular characterization of lymphatic endothelial cells , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[113] Winnie S. Liang,et al. A novel role for cyclooxygenase-2 in regulating vascular channel formation by human breast cancer cells , 2006, Breast Cancer Research.
[114] R. Ji. Lymphatic endothelial cells, tumor lymphangiogenesis and metastasis: New insights into intratumoral and peritumoral lymphatics , 2006, Cancer and Metastasis Reviews.
[115] C. Walker. Ophthalmology , 1859, Bristol medico-chirurgical journal.
[116] N. Ferrara,et al. The biology of vascular endothelial growth factor. , 1997, Endocrine reviews.
[117] C. Ozcan,et al. Reversible posterior leukoencephalopathy syndrome and bevacizumab. , 2006, The New England journal of medicine.
[118] A. Griffioen,et al. Molecular pathways of angiogenesis inhibition. , 2007, Biochemical and biophysical research communications.
[119] H. Kurz,et al. Platelet-derived growth factor-B induces transformation of fibrocytes into spindle-shaped myofibroblasts in vivo , 1998, Histochemistry and Cell Biology.
[120] Baocun Sun,et al. Hypoxia influences vasculogenic mimicry channel formation and tumor invasion-related protein expression in melanoma. , 2007, Cancer letters.
[121] Toshio Ohhashi,et al. PDGF-BB induces intratumoral lymphangiogenesis and promotes lymphatic metastasis. , 2004, Cancer cell.
[122] R. Hebbel,et al. Origins of circulating endothelial cells and endothelial outgrowth from blood. , 2000, The Journal of clinical investigation.
[123] O. Kocher,et al. Blood Markers for Vasculogenesis Increase with Tumor Progression in Patients with Breast Carcinoma , 2003, Cancer biology & therapy.
[124] Thomas N. Sato,et al. Leakage-resistant blood vessels in mice transgenically overexpressing angiopoietin-1. , 1999, Science.
[125] M. Skobe,et al. Therapeutic lymphangiogenesis with human recombinant VEGF‐C , 2002, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[126] D J Ruiter,et al. Quantitative immunohistological analysis of the microvasculature in untreated human glioblastoma multiforme. Computer-assisted image analysis of whole-tumor sections. , 1994, Journal of neurosurgery.
[127] D. Newton,et al. "Vasocrine" formation of tumor cell-lined vascular spaces: implications for rational design of antiangiogenic therapies. , 2003, Cancer research.
[128] S. Rafii,et al. Impaired recruitment of bone-marrow–derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth , 2001, Nature Medicine.
[129] William Arbuthnot Sir Lane,et al. Endostatin: An Endogenous Inhibitor of Angiogenesis and Tumor Growth , 1997, Cell.
[130] Christian A. Rees,et al. Molecular portraits of human breast tumours , 2000, Nature.
[131] D. Jackson,et al. LYVE-1, a New Homologue of the CD44 Glycoprotein, Is a Lymph-specific Receptor for Hyaluronan , 1999, The Journal of cell biology.
[132] Y. Miyagi,et al. Differential role of tissue factor pathway inhibitors 1 and 2 in melanoma vasculogenic mimicry. , 2003, Cancer research.
[133] Wei Zhang,et al. Vasculogenic mimicry is associated with high tumor grade, invasion and metastasis, and short survival in patients with hepatocellular carcinoma. , 2006, Oncology reports.
[134] K. Alitalo,et al. Adult bone marrow-derived cells recruited during angiogenesis comprise precursors for periendothelial vascular mural cells. , 2004, Blood.
[135] R. Jain. Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy , 2005, Science.
[136] R. Folberg,et al. The prognostic value of tumor blood vessel morphology in primary uveal melanoma. , 1993, Ophthalmology.
[137] Ruslan Hlushchuk,et al. Intussusceptive angiogenesis: Its emergence, its characteristics, and its significance , 2004, Developmental dynamics : an official publication of the American Association of Anatomists.
[138] W. Gerald,et al. Id1 and Id3 are required for neurogenesis, angiogenesis and vascularization of tumour xenografts , 1999, Nature.
[139] Mark A. Hall,et al. Hemostasis, Thrombosis, and Vascular Biology Materials and Methods Lacz and Platelet Endothelial Cell Adhesion Molecule 1 (pecam-1) Staining , 2022 .
[140] E. Tschachler,et al. Angiosarcomas express mixed endothelial phenotypes of blood and lymphatic capillaries: podoplanin as a specific marker for lymphatic endothelium. , 1999, The American journal of pathology.
[141] D. Sane,et al. Abnormal angiogenesis in diabetes mellitus , 2003, Medicinal research reviews.
[142] Giovanni Martinelli,et al. Continuous infusion of endostatin inhibits differentiation, mobilization, and clonogenic potential of endothelial cell progenitors. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[143] K. Alitalo,et al. Metastasis: Lymphangiogenesis and cancer metastasis , 2002, Nature Reviews Cancer.
[144] M. Karkkainen,et al. Abnormal lymphatic vessel development in neuropilin 2 mutant mice. , 2002, Development.
[145] J. Partanen,et al. Vascular endothelial growth factor C is required for sprouting of the first lymphatic vessels from embryonic veins , 2004, Nature Immunology.
[146] J. Isner,et al. VEGF contributes to postnatal neovascularization by mobilizing bone marrow‐derived endothelial progenitor cells , 1999, The EMBO journal.
[147] K. Nakano,et al. Angioarchitecture of Primary Oral Malignant Melanomas , 2002, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.
[148] R. Jain,et al. Intussusceptive microvascular growth in a human colon adenocarcinoma xenograft: a novel mechanism of tumor angiogenesis. , 1996, Microvascular research.
[149] Peter J. Polverini,et al. Regulation of the activity of a new inhibitor of angiogenesis by a cancer suppressor gene , 1989, Cell.
[150] D. Hicklin,et al. Effect of p53 Status on Tumor Response to Antiangiogenic Therapy , 2002, Science.
[151] K. Alitalo,et al. Angiopoietin-1 promotes LYVE-1-positive lymphatic vessel formation. , 2005, Blood.
[152] Wei Zhang,et al. Vasculogenic mimicry is associated with poor survival in patients with mesothelial sarcomas and alveolar rhabdomyosarcomas. , 2004, International journal of oncology.
[153] Rakesh K Jain,et al. Molecular regulation of vessel maturation , 2003, Nature Medicine.
[154] S. Duan,et al. Induction of tumor angiogenesis by Slit-Robo signaling and inhibition of cancer growth by blocking Robo activity. , 2003, Cancer cell.
[155] M. Halford,et al. Vascular Endothelial Growth Factor D Is Dispensable for Development of the Lymphatic System , 2005, Molecular and Cellular Biology.
[156] U. Schumacher,et al. PAS‐positive loops and networks as a prognostic indicator in cutaneous malignant melanoma , 2001, The Journal of pathology.
[157] M. Skobe,et al. Lymphatic endothelium , 2003, The Journal of cell biology.
[158] W. Muller,et al. CD99 plays a major role in the migration of monocytes through endothelial junctions , 2002, Nature Immunology.
[159] Lars Holmgren,et al. Dormancy of micrometastases: Balanced proliferation and apoptosis in the presence of angiogenesis suppression , 1995, Nature Medicine.
[160] A. Pozzi,et al. Soluble Eph A receptors inhibit tumor angiogenesis and progression in vivo , 2002, Oncogene.
[161] Gerard C Blobe,et al. Role of transforming growth factor Beta in human cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[162] P. Burri,et al. Evidence for intussusceptive capillary growth in the chicken chorio-allantoic membrane (CAM) , 1993, Anatomy and Embryology.
[163] A. Bosserhoff,et al. Functional implication of BMP4 expression on angiogenesis in malignant melanoma , 2006, Oncogene.
[164] Amato J Giaccia,et al. The hypoxic microenvironment of the skin contributes to Akt-mediated melanocyte transformation. , 2005, Cancer cell.
[165] M. Hendrix,et al. Embryonic and tumorigenic pathways converge via Nodal signaling: role in melanoma aggressiveness , 2006, Nature Medicine.
[166] M. Kreuter,et al. Semaphorin 3F, a chemorepulsant for endothelial cells, induces a poorly vascularized, encapsulated, nonmetastatic tumor phenotype. , 2004, The Journal of clinical investigation.
[167] M. Hendrix,et al. Angiogenesis: Vasculogenic mimicry and tumour-cell plasticity: lessons from melanoma , 2003, Nature Reviews Cancer.